Screener / SEC EDGAR /CIK 0000886163 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq, OTC Health care · Pharmaceuticals

Ligand Pharmaceuticals Inc LGND

Compare with peers Embed

LGND among the 162 companies we cover

Where it stands · the better end on the right. The band holds the middle half; the line is the median.

All 162
Sales growth
+4.8%+20.2%
+60.4%13th of 155 · median +10.5%
Net margin
-4.1%15.3%
20.3%23rd of 154 · median 6.8%
Return on equity
-5.2%18.5%
5.4%89th of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
35.7%6th of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
1.1783rd of 108 · median 0.69

LGND and 9 peers, year by year

The 9 Health care companies closest to LGND in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.

Choose the peers

Health care companies (up to 9):

Each company's latest fiscal year
CompanyYearRevenueSales growthGross marginOperating marginNet marginFCF marginReturn on equityDebt / equity
LGND Ligand Pharmaceuticals Inc FY2025 $268.1M+60.4%-15.3%46.4%18.2%12.2%-
LMAT Lemaitre Vascular Inc FY2025 $249.6M+13.5%71.5%27.2%23.1%29.8%14.7%-
RYTM Rhythm Pharmaceuticals, Inc. FY2025 $189.8M+45.8%-−101.2%−103.6%−61.5%−141.3%0.78
RVMD Revolution Medicines, Inc. FY2025 $0-----−69.3%-
VCEL Vericel Corp FY2025 $276.3M+16.5%74.4%4.0%6.0%9.0%4.7%-
GRAL GRAIL, Inc. FY2025 $147.2M+17.2%-−382.0%−277.5%−203.8%−15.8%-
PRCT PROCEPT BioRobotics Corp FY2025 $308.1M+37.2%63.7%−33.7%−31.0%−18.9%−26.1%0.14
BEAM Beam Therapeutics Inc. FY2025 $139.7M+120%-−274.6%−57.2%−257.7%−6.5%-
AGIO Agios Pharmaceuticals, Inc. FY2025 $54.0M+48.0%-−873.9%−764.0%−698.3%−34.6%-
CYTK Cytokinetics Inc FY2025 $88.0M+377%-−695.4%−891.6%−607.5%n/mn/m

Each company, year by year

Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2016 to FY2025 · 10-K XBRL

LGNDLigand Pharmaceuticals Inc
FY2016 revenue $109.0MFY2017 revenue $141.1MFY2018 revenue $251.5MFY2019 revenue $120.3MFY2020 revenue $163.6MFY2021 revenue $241.5MFY2022 revenue $196.2MFY2023 revenue $131.3MFY2024 revenue $167.1MFY2025 revenue $268.1M FY2016 net margin −1.5%FY2017 net margin 8.9%FY2018 net margin 57.0%FY2019 net margin 523.2%FY2020 net margin −1.8%FY2021 net margin 23.7%FY2022 net margin −17.0%FY2023 net margin 39.7%FY2024 net margin −2.4%FY2025 net margin 46.4% FY2016FY2025
Revenue$268.1M Growth+60.4% Net margin46.4%
LMATLemaitre Vascular Inc
FY2016 revenue $89.2MFY2017 revenue $100.9MFY2018 revenue $105.6MFY2019 revenue $117.2MFY2020 revenue $129.4MFY2021 revenue $154.4MFY2022 revenue $161.7MFY2023 revenue $193.5MFY2024 revenue $219.9MFY2025 revenue $249.6M FY2016 net margin 11.9%FY2017 net margin 17.0%FY2018 net margin 21.7%FY2019 net margin 15.3%FY2020 net margin 16.4%FY2021 net margin 17.4%FY2022 net margin 12.8%FY2023 net margin 15.6%FY2024 net margin 20.0%FY2025 net margin 23.1% FY2016FY2025
Revenue$249.6M Growth+13.5% Net margin23.1%
RYTMRhythm Pharmaceuticals, Inc.
FY2021 revenue $3.2MFY2022 revenue $23.6MFY2023 revenue $77.4MFY2024 revenue $130.1MFY2025 revenue $189.8M FY2022 net margin −766.2%FY2023 net margin −238.5%FY2024 net margin −200.3%FY2025 net margin −103.6% FY2016FY2025
Revenue$189.8M Growth+45.8% Net margin−103.6%
RVMDRevolution Medicines, Inc.
FY2018 revenue $20.2MFY2019 revenue $50.0MFY2020 revenue $43.0MFY2021 revenue $29.4MFY2022 revenue $35.4MFY2023 revenue $11.6M FY2018 net margin −207.2%FY2019 net margin −95.2%FY2020 net margin −251.6%FY2021 net margin −636.6%FY2022 net margin −703.0% FY2016FY2025
Revenue$0 Growth−100% Net margin−703.0%
VCELVericel Corp
FY2016 revenue $54.4MFY2017 revenue $63.9MFY2018 revenue $90.9MFY2019 revenue $117.8MFY2020 revenue $124.2MFY2021 revenue $156.2MFY2022 revenue $164.4MFY2023 revenue $197.5MFY2024 revenue $237.2MFY2025 revenue $276.3M FY2016 net margin −36.0%FY2017 net margin −27.0%FY2018 net margin −9.0%FY2019 net margin −8.2%FY2020 net margin 2.3%FY2021 net margin −4.8%FY2022 net margin −10.2%FY2023 net margin −1.6%FY2024 net margin 4.4%FY2025 net margin 6.0% FY2016FY2025
Revenue$276.3M Growth+16.5% Net margin6.0%
GRALGRAIL, Inc.
FY2022 revenue $55.5MFY2023 revenue $93.1MFY2024 revenue $125.6MFY2025 revenue $147.2M FY2025 net margin −277.5% FY2016FY2025
Revenue$147.2M Growth+17.2% Net margin−277.5%
PRCTPROCEPT BioRobotics Corp
FY2020 revenue $7.7MFY2021 revenue $34.5MFY2022 revenue $75.0MFY2023 revenue $136.2MFY2024 revenue $224.5MFY2025 revenue $308.1M FY2020 net margin −687.0%FY2021 net margin −173.6%FY2022 net margin −116.2%FY2023 net margin −77.8%FY2024 net margin −40.7%FY2025 net margin −31.0% FY2016FY2025
Revenue$308.1M Growth+37.2% Net margin−31.0%
BEAMBeam Therapeutics Inc.
FY2019 revenue $18KFY2020 revenue $24KFY2021 revenue $51.8MFY2022 revenue $60.9MFY2023 revenue $377.7MFY2024 revenue $63.5MFY2025 revenue $139.7M FY2021 net margin −714.9%FY2022 net margin −474.5%FY2023 net margin −35.1%FY2024 net margin −593.1%FY2025 net margin −57.2% FY2016FY2025
Revenue$139.7M Growth+120% Net margin−57.2%
AGIOAgios Pharmaceuticals, Inc.
FY2016 revenue $69.9MFY2017 revenue $43.0MFY2018 revenue $94.4MFY2019 revenue $117.9MFY2022 revenue $14.2MFY2023 revenue $26.8MFY2024 revenue $36.5MFY2025 revenue $54.0M FY2016 net margin −284.0%FY2017 net margin −731.6%FY2018 net margin −366.6%FY2019 net margin −349.0%FY2025 net margin −764.0% FY2016FY2025
Revenue$54.0M Growth+48.0% Net margin−764.0%
CYTKCytokinetics Inc
FY2016 revenue $106.4MFY2017 revenue $13.4MFY2018 revenue $31.5MFY2019 revenue $26.9MFY2020 revenue $55.8MFY2021 revenue $70.4MFY2022 revenue $94.6MFY2023 revenue $7.5MFY2024 revenue $18.5MFY2025 revenue $88.0M FY2016 net margin 15.5%FY2017 net margin −955.9%FY2018 net margin −337.4%FY2019 net margin −452.9%FY2020 net margin −228.0%FY2021 net margin −305.7%FY2022 net margin −411.2%FY2025 net margin −891.6% FY2016FY2025
Revenue$88.0M Growth+377% Net margin−891.6%

Who rewrote the most

Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before

Risk FactorsMD&AEach company's latest 10-K, so the dates differ. A company that rewrote much may have reorganized the text.

Revenue, FY2016 to FY2025

Revenue as reported in the 10-K.

$0 $377.7M FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 LMAT: $89.2M, $100.9M, $105.6M, $117.2M, $129.4M, $154.4M, $161.7M, $193.5M, $219.9M, $249.6M LMAT RYTM: $0, $0, $0, $0, $0, $3.2M, $23.6M, $77.4M, $130.1M, $189.8M RYTM RVMD: -, -, $20.2M, $50.0M, $43.0M, $29.4M, $35.4M, $11.6M, $0, $0 RVMD VCEL: $54.4M, $63.9M, $90.9M, $117.8M, $124.2M, $156.2M, $164.4M, $197.5M, $237.2M, $276.3M VCEL GRAL: -, -, -, -, -, -, $55.5M, $93.1M, $125.6M, $147.2M GRAL PRCT: -, -, -, -, $7.7M, $34.5M, $75.0M, $136.2M, $224.5M, $308.1M PRCT BEAM: -, -, -, $18K, $24K, $51.8M, $60.9M, $377.7M, $63.5M, $139.7M BEAM AGIO: $69.9M, $43.0M, $94.4M, $117.9M, $0, $0, $14.2M, $26.8M, $36.5M, $54.0M AGIO CYTK: $106.4M, $13.4M, $31.5M, $26.9M, $55.8M, $70.4M, $94.6M, $7.5M, $18.5M, $88.0M CYTK LGND: $109.0M, $141.1M, $251.5M, $120.3M, $163.6M, $241.5M, $196.2M, $131.3M, $167.1M, $268.1M LGND
LGND is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from $0 to $377.7M. A gap is a year with no number. A ring marks where a line starts: RVMD, GRAL, PRCT, BEAM have no earlier 10-K here. LGND: the line is cut where a later 10-K restates the year before (a spin-off or a merger), so the two years are not the same company.

Sales growth, FY2016 to FY2025

Revenue against the fiscal year before.

−100% +649% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 LMAT: +13.8%, +13.1%, +4.7%, +11.0%, +10.4%, +19.4%, +4.7%, +19.7%, +13.6%, +13.5% LMAT RYTM: -, -, -, -, -, -, +649%, +228%, +68.1%, +45.8% RYTM RVMD: -, -, -, +148%, −14.1%, −31.6%, +20.4%, −67.3%, −100%, - RVMD VCEL: +6.3%, +15.4%, +44.8%, +29.7%, +3.5%, +25.5%, +6.9%, +20.7%, +20.1%, +16.5% VCEL GRAL: -, -, -, -, -, -, -, +67.6%, +34.9%, +17.2% GRAL PRCT: -, -, -, -, -, +347%, +118%, +81.6%, +64.8%, +37.2% PRCT BEAM: -, -, -, -, +33.3%, n/m, +17.5%, +520%, −83.2%, +120% BEAM AGIO: +18.2%, −38.5%, +119%, +24.9%, −100%, -, -, +88.4%, +36.1%, +48.0% AGIO CYTK: +271%, −87.4%, +136%, −14.7%, +108%, +26.2%, +34.3%, −92.0%, +145%, +377% CYTK LGND: +51.5%, +29.5%, +78.2%, −52.2%, +55.0%, +47.7%, −18.8%, −33.1%, +27.3%, +60.4% LGND
LGND is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −100% to +649%. A gap is a year with no number. A ring marks where a line starts: RYTM, RVMD, GRAL, PRCT, BEAM have no earlier 10-K here.

Gross margin, FY2016 to FY2025

Gross profit / revenue.

−16.3% 74.4% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 LMAT: 70.6%, 70.1%, 70.0%, 68.1%, 65.4%, 65.7%, 64.9%, 65.7%, 68.6%, 71.5% LMAT VCEL: 47.9%, 52.5%, 64.6%, 68.1%, 67.8%, 67.9%, 66.8%, 68.6%, 72.6%, 74.4% VCEL PRCT: -, -, -, -, −16.3%, 46.0%, 49.4%, 52.2%, 61.1%, 63.7% PRCT
LGND is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −16.3% to 74.4%. A gap is a year with no number. A ring marks where a line starts: PRCT has no earlier 10-K here.
CompanyFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
LGND Dec ----------
LMAT Dec 70.6%70.1%70.0%68.1%65.4%65.7%64.9%65.7%68.6%71.5%
RYTM Dec ----------
RVMD Dec ----------
VCEL Dec 47.9%52.5%64.6%68.1%67.8%67.9%66.8%68.6%72.6%74.4%
GRAL Dec ----------
PRCT Dec ----−16.3%46.0%49.4%52.2%61.1%63.7%
BEAM Dec ----------
AGIO Dec ----------
CYTK Dec ----------
Peer median----65.4%65.7%64.9%65.7%68.6%71.5%

Operating margin, FY2016 to FY2025

Operating income / revenue.

−873.9% 671.0% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 LMAT: 18.3%, 20.9%, 26.7%, 18.1%, 22.3%, 23.6%, 16.6%, 19.0%, 23.8%, 27.2% LMAT RYTM: -, -, -, -, -, n/m, −757.9%, −238.1%, −204.0%, −101.2% RYTM RVMD: -, -, −200.0%, −108.2%, −257.5%, −639.7%, −730.0%, n/m, -, - RVMD VCEL: −35.4%, −23.4%, −4.3%, −9.5%, 1.9%, −5.0%, −10.4%, −3.3%, 1.9%, 4.0% VCEL GRAL: -, -, -, -, -, -, n/m, n/m, n/m, −382.0% GRAL PRCT: -, -, -, -, −619.4%, −157.1%, −107.6%, −80.2%, −43.0%, −33.7% PRCT BEAM: -, -, -, n/m, n/m, −757.0%, −555.6%, −46.7%, −654.3%, −274.6% BEAM AGIO: −287.6%, −745.8%, −384.0%, −268.2%, -, -, n/m, n/m, n/m, −873.9% AGIO CYTK: 17.6%, −848.3%, −282.3%, −368.0%, −168.3%, −264.5%, −342.8%, n/m, n/m, −695.4% CYTK LGND: 40.3%, 48.2%, 65.1%, 671.0%, 22.9%, 43.0%, 1.5%, 9.1%, −13.5%, 15.3% LGND
LGND is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −873.9% to 671.0%. A gap is a year with no number. A ring marks where a line starts: RYTM, RVMD, GRAL, PRCT, BEAM have no earlier 10-K here.

Net margin, FY2016 to FY2025

Net income / revenue.

−955.9% 523.2% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 LMAT: 11.9%, 17.0%, 21.7%, 15.3%, 16.4%, 17.4%, 12.8%, 15.6%, 20.0%, 23.1% LMAT RYTM: -, -, -, -, -, n/m, −766.2%, −238.5%, −200.3%, −103.6% RYTM RVMD: -, -, −207.2%, −95.2%, −251.6%, −636.6%, −703.0%, n/m, -, - RVMD VCEL: −36.0%, −27.0%, −9.0%, −8.2%, 2.3%, −4.8%, −10.2%, −1.6%, 4.4%, 6.0% VCEL GRAL: -, -, -, -, -, -, n/m, n/m, n/m, −277.5% GRAL PRCT: -, -, -, -, −687.0%, −173.6%, −116.2%, −77.8%, −40.7%, −31.0% PRCT BEAM: -, -, -, n/m, n/m, −714.9%, −474.5%, −35.1%, −593.1%, −57.2% BEAM AGIO: −284.0%, −731.6%, −366.6%, −349.0%, -, -, n/m, n/m, n/m, −764.0% AGIO CYTK: 15.5%, −955.9%, −337.4%, −452.9%, −228.0%, −305.7%, −411.2%, n/m, n/m, −891.6% CYTK LGND: −1.5%, 8.9%, 57.0%, 523.2%, −1.8%, 23.7%, −17.0%, 39.7%, −2.4%, 46.4% LGND
LGND is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −955.9% to 523.2%. A gap is a year with no number. A ring marks where a line starts: RYTM, RVMD, GRAL, PRCT, BEAM have no earlier 10-K here.

Free cash flow, FY2016 to FY2025

Cash from operations minus capital spending.

−$913.7M $193.2M FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 LMAT: $14.1M, $16.5M, $16.5M, $10.4M, $31.8M, $30.2M, $22.1M, $29.5M, $37.2M, $74.5M LMAT RYTM: −$24.3M, −$29.6M, −$62.8M, −$126.1M, −$122.2M, −$146.4M, −$173.7M, −$136.2M, −$113.9M, −$116.6M RYTM RVMD: -, -, −$286K, −$52.2M, −$103.0M, −$153.7M, −$235.2M, −$358.3M, −$567.7M, −$913.7M RVMD VCEL: −$21.3M, −$14.7M, −$3.1M, −$9.8M, $14.9M, $21.1M, $10.1M, $15.3M, −$5.8M, $24.7M VCEL GRAL: -, -, -, -, -, -, −$584.2M, −$608.7M, −$582.4M, −$299.9M GRAL PRCT: -, -, -, -, −$48.6M, −$57.9M, −$83.0M, −$133.2M, −$103.6M, −$58.3M PRCT BEAM: -, -, -, −$84.5M, −$112.1M, −$113.1M, −$26.4M, −$182.9M, −$356.2M, −$360.0M BEAM AGIO: $28.6M, −$289.9M, −$311.4M, −$382.6M, −$304.9M, −$413.1M, −$314.4M, −$297.1M, −$391.5M, −$377.3M AGIO CYTK: $35.4M, −$104.6M, −$102.1M, −$93.5M, −$2.1M, −$191.4M, −$310.9M, −$415.7M, −$399.8M, −$534.8M CYTK LGND: $58.9M, $86.4M, $193.2M, −$31.9M, $50.1M, $70.0M, $119.9M, $46.1M, $95.2M, $48.9M LGND
LGND is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$913.7M to $193.2M. A gap is a year with no number. A ring marks where a line starts: RVMD, GRAL, PRCT, BEAM have no earlier 10-K here.

FCF margin, FY2016 to FY2025

Free cash flow / revenue.

−782.7% 76.8% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 LMAT: 15.8%, 16.3%, 15.6%, 8.9%, 24.6%, 19.6%, 13.7%, 15.2%, 16.9%, 29.8% LMAT RYTM: -, -, -, -, -, n/m, −734.9%, −175.9%, −87.5%, −61.5% RYTM RVMD: -, -, −1.4%, −104.3%, −239.6%, −523.0%, −664.8%, n/m, -, - RVMD VCEL: −39.2%, −23.0%, −3.4%, −8.3%, 12.0%, 13.5%, 6.1%, 7.7%, −2.4%, 9.0% VCEL GRAL: -, -, -, -, -, -, n/m, −653.8%, −463.7%, −203.8% GRAL PRCT: -, -, -, -, −629.5%, −168.0%, −110.7%, −97.8%, −46.2%, −18.9% PRCT BEAM: -, -, -, n/m, n/m, −218.1%, −43.4%, −48.4%, −560.8%, −257.7% BEAM AGIO: 41.0%, −673.9%, −329.9%, −324.5%, -, -, n/m, n/m, n/m, −698.3% AGIO CYTK: 33.3%, −782.7%, −324.1%, −348.1%, −3.8%, −271.8%, −328.6%, n/m, n/m, −607.5% CYTK LGND: 54.0%, 61.2%, 76.8%, −26.5%, 30.6%, 29.0%, 61.1%, 35.1%, 57.0%, 18.2% LGND
LGND is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −782.7% to 76.8%. A gap is a year with no number. A ring marks where a line starts: RYTM, RVMD, GRAL, PRCT, BEAM have no earlier 10-K here.

Return on equity, FY2016 to FY2025

Net income / shareholders' equity at the year end.

−141.3% 124.2% FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 LMAT: 12.1%, 15.6%, 17.6%, 12.1%, 12.3%, 10.6%, 7.7%, 10.1%, 13.1%, 14.7% LMAT RYTM: n/m, −23.3%, −30.1%, −50.1%, −80.5%, −24.5%, −68.5%, −108.8%, n/m, −141.3% RYTM RVMD: -, -, n/m, n/m, −22.8%, −31.0%, −36.3%, −23.9%, −26.5%, −69.3% RVMD VCEL: −79.2%, −76.7%, −8.0%, −8.7%, 2.1%, −4.4%, −8.7%, −1.4%, 3.5%, 4.7% VCEL GRAL: -, -, -, -, -, -, -, -, −81.0%, −15.8% GRAL PRCT: -, -, -, -, n/m, −22.4%, −44.2%, −37.7%, −22.7%, −26.1% PRCT BEAM: -, -, -, n/m, −79.2%, −44.8%, −39.4%, −13.5%, −51.4%, −6.5% BEAM AGIO: −55.3%, −83.8%, −50.3%, −64.2%, −81.9%, 124.2%, −21.1%, −43.4%, 43.7%, −34.6% AGIO CYTK: 17.4%, −116.3%, n/m, n/m, −112.3%, −88.3%, n/m, n/m, n/m, n/m CYTK LGND: −0.5%, 3.1%, 25.6%, 82.0%, −0.4%, 7.0%, −5.6%, 7.4%, −0.5%, 12.2% LGND
LGND is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −141.3% to 124.2%. A gap is a year with no number. A ring marks where a line starts: RYTM, RVMD, GRAL, PRCT, BEAM have no earlier 10-K here.

Debt / equity, FY2016 to FY2025

Total debt / shareholders' equity at the year end.

0.13 5.05 FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 RYTM: -, -, -, -, -, -, -, 0.63, 5.05, 0.78 RYTM VCEL: 0.38, 0.75, -, -, -, -, -, -, -, - VCEL PRCT: -, -, -, -, n/m, 0.19, 0.26, 0.18, 0.13, 0.14 PRCT CYTK: 0.32, 0.29, 1.64, n/m, 0.41, 0.19, n/m, n/m, n/m, n/m CYTK
LGND is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 0.13 to 5.05. A gap is a year with no number. A ring marks where a line starts: RYTM, PRCT have no earlier 10-K here.
CompanyFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
LGND Dec ----------
LMAT Dec ----------
RYTM Dec -------0.635.050.78
RVMD Dec ----------
VCEL Dec 0.380.75--------
GRAL Dec ----------
PRCT Dec ----n/m0.190.260.180.130.14
BEAM Dec ----------
AGIO Dec ----------
CYTK Dec 0.320.291.64n/m0.410.19n/mn/mn/mn/m
Peer median----------

EPS (diluted), FY2016 to FY2025

Diluted earnings per share, on today's share count after splits.

−$173.89 $31.85 FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025 LMAT: $0.55, $0.86, $1.13, $0.88, $1.04, $1.25, $0.93, $1.34, $1.93, $2.52 LMAT RYTM: −$2.85, −$2.83, −$2.39, −$3.86, −$3.04, −$1.40, −$3.47, −$3.20, −$4.34, −$3.11 RYTM RVMD: -, -, −$21.24, −$22.33, −$2.01, −$2.57, −$3.08, −$3.86, −$3.58, −$5.95 RVMD VCEL: −$1.18, −$0.52, −$0.20, −$0.22, $0.06, −$0.16, −$0.35, −$0.07, $0.20, $0.32 VCEL GRAL: -, -, -, -, -, -, −$173.89, −$47.21, −$63.54, −$11.11 GRAL PRCT: -, -, -, -, −$14.47, −$3.63, −$1.96, −$2.24, −$1.75, −$1.72 PRCT BEAM: -, -, -, −$14.05, −$4.19, −$5.77, −$4.13, −$1.72, −$4.58, −$0.81 BEAM AGIO: −$5.07, −$6.75, −$6.03, −$6.86, −$4.74, $26.55, −$4.23, −$6.33, $11.64, −$7.12 AGIO CYTK: $0.39, −$2.59, −$1.95, −$2.11, −$1.97, −$2.80, −$4.33, −$5.45, −$5.26, −$6.54 CYTK LGND: −$0.08, $0.53, $5.96, $31.85, −$0.18, $3.31, −$1.98, $2.94, −$0.22, $6.13 LGND
LGND is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$173.89 to $31.85. A gap is a year with no number. A ring marks where a line starts: RVMD, GRAL, PRCT, BEAM have no earlier 10-K here.

Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out LGND and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more

Sources

Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.

Also

Financials: LGND's own statements, year by year. Compare: the whole peer group on one page.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/LGND/export.csv") into a cell.

Next:Industry numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.